Core Points - The 2025 National Medical Insurance Directory negotiations have officially commenced, highlighting the importance of pharmaceutical innovation and patient access to medications [1] - The atmosphere at the negotiations is characterized by a cautious and low-key approach from pharmaceutical representatives, with an increased emphasis on confidentiality [3][4] - A total of 535 drugs are under review, with 311 outside the directory and 224 within it, alongside 121 high-value drugs reviewed under the commercial insurance innovation drug directory [9][10] Group 1: Negotiation Atmosphere - The entry process for pharmaceutical representatives was notably quieter and more orderly compared to previous years, reflecting a more subdued approach [3][4] - Representatives from both domestic and multinational pharmaceutical companies, including notable names like 恒瑞医药 and 阿斯利康, participated in the negotiations [4][9] Group 2: Key Drug Categories - Antibacterial drugs are expected to be a significant focus in the afternoon session of the negotiations, with specific products like 万古霉素 being highlighted [9][10] - Innovative drugs, including CAR-T products and new lipid-lowering medications, are also under consideration, with 恒瑞医药 presenting multiple products for initial review [10][12] Group 3: Market Insights - The PCSK9 inhibitor 瑞卡西单抗 has gained attention for its long-acting properties, with a market size of 1.32 billion yuan in 2023, representing 7.8% of the national lipid-lowering drug market [10][11] - The long-acting 阿立哌唑微球 from 丽珠集团 is another product of interest, potentially replacing oral formulations and capturing market share if included in the insurance directory [12]

Group 1: Market Performance - The Hong Kong Innovative Drug Selected ETF (520690) increased by 0.22%, with the latest price at 0.89 yuan as of October 29, 2025 [3] - The ETF recorded a turnover of 4.25% during the trading session, with a total transaction value of 21.78 million yuan [3] - Over the past year, the average daily transaction volume of the ETF was 120 million yuan [3] Group 2: Clinical Data and Industry Insights - Grail presented initial data from its multi-cancer early detection product Galleri at the 2025 ESMO annual meeting, showing a positive predictive value of 61.6% and a specificity of 99.6% [3] - Among the detected new cancers, 69.3% were in stages I-III, with a tissue origin accuracy of 91.7% [3] - Guosen Securities views this data as a significant milestone in the multi-cancer early detection field, suggesting Galleri could enhance existing screening systems [3] Group 3: Company Earnings and Trends - Over 280 pharmaceutical and biotech companies, including Heng Rui Pharmaceutical and WuXi AppTec, reported strong Q3 results, driven by advancements in R&D pipelines and new drug launches [3] - The overall industry is exhibiting a positive trend characterized by "innovation as a foundation and overseas expansion" [3] Group 4: CDMO Sector Performance - Lonza, a leading overseas CDMO, reported strong Q3 results, maintaining a revenue growth forecast of 20-21% for the year, with core EBITDA margins between 30-31% [4] - Medpace has seen consecutive growth in new orders for two quarters, indicating a recovering financing environment for U.S. small and mid-sized biotech firms [4] - WuXi AppTec exceeded Q3 performance expectations and raised its full-year guidance, further confirming the positive outlook for the CXO industry [4] Group 5: ETF Size and Inflows - The latest size of the Hong Kong Innovative Drug Selected ETF reached 512 million yuan, marking a new high since its inception [4] - The ETF's share count also hit a record high of 574 million shares [4] - In the past five days, the ETF experienced continuous net inflows, with a peak single-day net inflow of 31.48 million yuan, totaling 82.81 million yuan in net inflows [4]

Core Insights - The top three companies by Hong Kong Stock Connect holding ratios are China Telecom (00728) at 71.18%, COSCO Shipping Energy (01138) at 70.26%, and GCL-Poly Energy (01330) at 70.25% [1] - In the last five trading days, the largest increases in holding amounts were seen in CNOOC (00883) with an increase of 3.009 billion, SMIC (00981) with 1.746 billion, and Meituan-W (03690) with 1.364 billion [1] - The largest decreases in holding amounts were recorded for Hua Hong Semiconductor (01347) at -1.499 billion, Stone Pharmaceutical (01093) at -1.209 billion, and China Biologic Products (01177) at -0.606 billion [3] Group 1: Top Holding Ratios - China Telecom (00728) holds 9.879 billion shares, representing 71.18% [1] - COSCO Shipping Energy (01138) holds 911 million shares, representing 70.26% [1] - GCL-Poly Energy (01330) holds 284 million shares, representing 70.25% [1] Group 2: Recent Increases in Holdings - CNOOC (00883) saw an increase of 3.009 billion, with a change of 15.08289 million shares [1] - SMIC (00981) increased by 1.746 billion, with a change of 2.18015 million shares [1] - Meituan-W (03690) increased by 1.364 billion, with a change of 1.36405 million shares [1] Group 3: Recent Decreases in Holdings - Hua Hong Semiconductor (01347) decreased by 1.499 billion, with a change of -1.74038 million shares [3] - Stone Pharmaceutical (01093) decreased by 1.209 billion, with a change of -15.71580 million shares [3] - China Biologic Products (01177) decreased by 0.606 billion, with a change of -8.61388 million shares [3]

Core Insights - The article highlights the net inflow and outflow of funds for various companies in the Hong Kong stock market, indicating significant movements in investor sentiment and market dynamics [1][2][3] Net Inflow Summary - Meituan-W (03690) leads with a net inflow of 653 million, representing a 12.11% increase in its closing price to 100.600 [2] - Semiconductor Manufacturing International Corporation (00981) follows with a net inflow of 590 million, with an 8.04% increase in its closing price to 80.000 [2] - China National Offshore Oil Corporation (00883) has a net inflow of 570 million, showing a 0.50% increase in its closing price to 20.020 [2] - Other notable inflows include Tencent Holdings (00700) with 374 million and a 0.71% increase, and Horizon Robotics-W (09660) with 349 million and a 6.35% increase [2] Net Outflow Summary - CSPC Pharmaceutical Group (01093) experiences the highest net outflow of 650 million, with a 3.90% decrease in its closing price to 7.890 [2] - Pop Mart International (09992) follows with a net outflow of 642 million, down 0.86% to 230.400 [2] - UBTECH Robotics (09880) sees a net outflow of 295 million, with a 6.81% increase in its closing price to 142.700 [2] - Other significant outflows include BYD Electronic (00285) with 249 million and a 1.97% increase, and Jingtai Holdings (02228) with 184 million and a 2.98% increase [2] Net Inflow Ratio Summary - China Merchants Port (00144) leads with a net inflow ratio of 69.84%, closing at 15.210 with a 0.40% increase [3] - Greentown Service (02869) follows with a 64.68% net inflow ratio, closing at 4.680 with a 1.30% increase [3] - Tong Ren Tang Technologies (03613) has a net inflow ratio of 63.56%, closing at 8.710 with a 0.80% decrease [3] Net Outflow Ratio Summary - E Fund Hang Seng ESG (03039) shows a net outflow ratio of -100.00%, closing at 3.902 with a 0.88% increase [3] - 康诺亚-B (02162) has a net outflow ratio of -58.25%, closing at 59.100 with a 2.80% decrease [3] - SF Express (06936) follows with a -56.29% net outflow ratio, closing at 36.860 with a 0.54% decrease [3]

Core Insights - The Hong Kong Innovative Drug ETF (159567) closed down 1.32% with a trading volume of 588 million yuan on October 28, 2024 [1] - The fund was established on January 3, 2024, with an annual management fee of 0.50% and a custody fee of 0.10% [1] - As of October 27, 2024, the fund's latest share count was 8.177 billion shares, with a total size of 6.823 billion yuan, reflecting a significant increase in both share count and size compared to the previous year [1] Fund Performance - The fund's share count increased by 1968.15% and its size increased by 1706.06% from December 31, 2023, when it had 395 million shares and a size of 378 million yuan [1] - The fund has recorded a total trading amount of 22.001 billion yuan over the last 20 trading days, averaging 1.1 billion yuan per day [1] - Year-to-date, the cumulative trading amount is 229.668 billion yuan, with an average daily trading amount of 1.166 billion yuan [1] Fund Management - The current fund manager is Ma Jun, who has managed the fund since its inception, achieving a return of 66.90% during the management period [2] - The top holdings of the fund include companies such as BeiGene, CanSino Biologics, Innovent Biologics, and others, with significant percentages of the portfolio allocated to these stocks [2] - The largest holding is BeiGene, accounting for 10.62% of the portfolio, followed by CanSino Biologics at 10.55% and Innovent Biologics at 10.21% [2]

Core Insights - The top three companies by Hong Kong Stock Connect holding ratios are China Telecom (71.16%), Gree Power Environmental (70.40%), and COSCO Shipping Energy (70.32%) [1] - In the last five trading days, the largest increases in holding amounts were seen in CNOOC (+2.948 billion), Pop Mart (+2.005 billion), and SMIC (+1.319 billion) [1] - The largest decreases in holding amounts were recorded for Hua Hong Semiconductor (-1.093 billion), Hang Seng China Enterprises (-603 million), and CSPC Pharmaceutical (-596 million) [2] Group 1: Hong Kong Stock Connect Holding Ratios - China Telecom (00728) has a holding ratio of 71.16% with 9.876 billion shares [1] - Gree Power Environmental (01330) has a holding ratio of 70.40% with 285 million shares [1] - COSCO Shipping Energy (01138) has a holding ratio of 70.32% with 911 million shares [1] Group 2: Recent Increases in Holdings - CNOOC (00883) saw an increase of 2.948 billion in holding amount, with a change of 14.69495 million shares [1] - Pop Mart (09992) experienced an increase of 2.005 billion in holding amount, with a change of 8.5892 million shares [1] - SMIC (00981) had an increase of 1.319 billion in holding amount, with a change of 1.59294 million shares [1] Group 3: Recent Decreases in Holdings - Hua Hong Semiconductor (01347) had a decrease of 1.093 billion in holding amount, with a change of -12.6364 million shares [2] - Hang Seng China Enterprises (02828) saw a decrease of 603 million in holding amount, with a change of -6.2396 million shares [2] - CSPC Pharmaceutical (01093) experienced a decrease of 596 million in holding amount, with a change of -7.65722 million shares [2]

Core Insights - The article highlights the net inflow and outflow of funds for various companies in the Hong Kong stock market, indicating significant movements in capital investment [1][2]. Net Inflow Summary - China Mobile (00941) leads with a net inflow of 1.131 billion, representing a 42.43% increase in investment [2]. - China National Offshore Oil Corporation (00883) follows with a net inflow of 979 million, showing a 28.62% increase [2]. - Pop Mart (09992) ranks third with a net inflow of 782 million, but its share price decreased by 9.36% [2]. Net Outflow Summary - Hua Hong Semiconductor (01347) experiences the highest net outflow at -1.018 billion, with a decrease of 22.36% [2]. - The iShares Asia 50 ETF (02800) has a net outflow of -795 million, reflecting a 6.53% decrease [2]. - Stone Pharmaceutical Group (01093) sees a net outflow of -488 million, with a 26.11% drop in investment [2]. Net Inflow Ratio Summary - GX Hangseng Technology (02837) has the highest net inflow ratio at 67.25%, with a net inflow of 14.7513 million [3]. - Tong Ren Tang (03613) follows with a net inflow ratio of 65.42%, amounting to 4.8958 million [3]. - Shenwei Pharmaceutical (02877) ranks third with a net inflow ratio of 54.29%, totaling 3.1420 million [3]. Net Outflow Ratio Summary - The Wisdom Hong Kong 100 ETF (02825) shows a net outflow ratio of -100.00%, with a total outflow of -5.972 million [3]. - China International Marine Containers (02039) has a net outflow ratio of -63.47%, amounting to -19.7122 million [3]. - Eagle Holdings (00041) follows with a net outflow ratio of -60.44%, totaling -5.7119 million [3].

Core Viewpoint - The company reported a revenue of 1.593 billion yuan for the first three quarters, reflecting a year-on-year increase of 7.71%, but also recorded a net loss attributable to shareholders of 24.0489 million yuan, with a basic loss per share of 0.0173 yuan [1] Financial Performance - Revenue for the first three quarters reached 1.593 billion yuan, which is a 7.71% increase compared to the previous year [1] - The net loss attributable to shareholders was 24.0489 million yuan [1] - Basic loss per share was reported at 0.0173 yuan [1]

Core Insights - The company reported a revenue of 1.593 billion yuan for the first three quarters, representing a year-on-year increase of 7.71% [1] - The net loss attributable to shareholders was 24.0489 million yuan, with a basic loss per share of 0.0173 yuan [1] Financial Performance - Revenue: 1.593 billion yuan, up 7.71% year-on-year [1] - Net Loss: 24.0489 million yuan [1] - Basic Loss per Share: 0.0173 yuan [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 份 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 CSPC PHARMACEUTICAL GROUP LIMITED 石藥集團有限公司 （股份代號：1093） （於香港註冊成立之有限公司） 石 藥 創 新 製 藥 股 份 有 限 公 司 截 至2025年9月30日 止 九 個 月 之 未 經 審 核 財 務 資 料 按 深 圳 證 券 交 易 所 之 相 關 規 定，石 藥 集 團 有 限 公 司（「本 公 司」）附 屬 公 司 石 藥 創 新 製 藥 股 份 有 限 公 司（「石 藥 創 新」，其 股 份 於 深 圳 證 券 交 易 所 創 業 板 上 市（股 票 代 碼：300765））， 已 於2025年10月27日 發 佈 其 截 至2025年9月30日 止 九 ...